Domainex Appoints Timo Veromaa as Executive Chairman
Dr Timo Veromaa. Credit: Domainex Ltd
Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce that Dr Timo Veromaa has been appointed Executive Chairman with immediate effect. His appointment expands and strengthens the existing Board and Executive Management Team; Dr Veromaa will have a pivotal role in leading the organisation through a continuing period of growth and investment. In the past 12 months, Domainex has doubled its laboratory space with a move to the Domainex Medicines Research Centre on the Chesterford Research Park near Cambridge, and has expanded its international team of scientists by more than 50%.
‘I am thrilled to join Domainex at this exciting stage of the company’s development,’ said Dr. Veromaa. ‘Domainex enjoys an outstanding reputation for scientific excellence in drug discovery. I believe we are in a strong position to build on our capabilities to serve our global client base. I look forward to developing and implementing our future growth strategies in drug discovery services.’
Dr. Veromaa brings a wealth of commercial success and drug discovery experience; he was President and CEO of Biotie Therapies Corporation for over 11 years until its acquisition by Acorda Therapeutics in 2016. During this period he achieved significant growth in the company, including the launch of Selincro® (an opioid antagonist), and a listing on the US Nasdaq stock exchange. During his earlier career he was a Medical Director of Schering Ltd. in Finland, Senior Scientist and Project Director at Collagen Corporation and a Postdoctoral Fellow at Stanford University in California. He is a medical doctor with a PhD in immunology from the University of Turku, Finland.
‘We are delighted to welcome Timo Veromaa as our Executive Chairman’, commented Trevor Perrior PhD, Chief Scientific Officer for Domainex. ‘His track record of blending commercial success with scientific innovation is evident. Domainex has come a long way since it was established in 2001 and we are exploring a number of exciting growth opportunities that will enable us to broaden the range of services we offer our clients.’
This article has been republished from materials provided by Domainex Ltd. Note: material may have been edited for length and content. For further information, please contact the cited source.
Lonza Introduces the New CytoSMART™ 2 System for Live Cell ImagingNews
Lonza's updated CytoSMART System has an advanced optical system to enable researchers to capture high-resolution images of their cell cultures.READ MORE
Sharpest Image of Alzheimer’s Fibrils Shows Previously Unknown DetailsNews
The fibrils of the body's own amyloid beta (Aβ) protein are the main constituent of Alzheimer's disease-related and characteristic pathological protein deposits in the brain.READ MORE